Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
National Inst. of Pharma Education and Research-Ahmedabad (NIPER-A) PKM2 compound 7d: sourced facts only. name: "Herein, we report the rational development of an imidazopyridine-based thiazole derivative 7d as an anticancer agent inhibiting PKM2." [PMID:38408027]; target: "Herein, we report the rational development of an imidazopyridine-based thiazole derivative 7d as an anticancer agent inhibiting PKM2." [PMID:38408027]; developer: "Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), Opposite Airforce station, Palaj, Gandhinagar, Gujarat 382355, India." [PMID:38408027]; stage: "In vivo, 7d outperformed lapatinib in tumor regression." [PMID:38408027]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on National Inst. of Pharma Education and Research-Ahmedabad (NIPER-A) PKM2 compound 7d.